- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04793984
Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients
Study Overview
Detailed Description
The tolerability and efficacy of inhaled Carragelose® will be investigated in a randomized, double blind, placebo-controlled trial in hospitalized COVID-19 patients.
Patients will inhale Inhaleen or Placebo 3 times a day for 7 minutes for 5 days.
The primary objective of the trial is to demonstrate that Inhaleen inhalation improves the clinical status of hospitalized COVID-19 patients on day 8 compared to placebo inhalation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1210
- Gesundheitsverbund, Klinik Floridsdorf
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained before any trial related procedures are performed
- Age ≥ 18 years
- Hospitalized patients with PCR confirmed SARS-CoV-2 infection and symptom onset ≤ 10 days before randomization
- Patients with respiratory COVID-19 symptoms
- Randomization ≤ 48h from admission
- Peripheral capillary oxygen saturation (SpO2) ≥ 90% on room air or supplemental oxygen at screening
- Patient agrees to refrain from taking other carragelose products (e.g. throat spray, lozenges)
Exclusion Criteria:
- No informed consent
- Persistent hypoxemia with SpO2 < 90% despite supplemental oxygen of > 6LO2/min at screening.
- Patients with predominantly extrapulmonary COVID-19 symptoms (e.g. gastrointestinal, neurological, etc.)
- Subjects who demonstrate respiratory and/or cardiac instability that is considered by the investigator as a reason for exclusion. Additionally, any other clinically significant disease that could interfere with participation in the study, with the intervention being studied, or with the evaluation of symptoms. Specific exclusions are asthma, immune deficiency, autoimmune disease, clinically significant cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease or any disease that is considered by the investigator as a reason for exclusion.
- Known hypersensitivity or allergy to any component of the test product
- The subject is related to any study personnel or has any other close ties or conflicts of interest with the study sponsor.
- The subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study
- Current medication other than oral contraception,that is considered by the investigator as a reason for exclusion.
- Pregnant/lactating women at the time of recruitment will be excluded from the study
- Participation in another antiviral clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inhaleen
Iota-Carrageenan inhalation
|
inhalation 3 times a day
Other Names:
|
Placebo Comparator: Placebo
NaCl inhalation
|
inhalation 3 times a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical status of subjects as expressed on the WHO-8-Category ordinal scale:
Time Frame: day 8
|
|
day 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cycle threshold of SARS-CoV-2 PCR·
Time Frame: until day 15
|
until day 15
|
|
multiplex viral examination
Time Frame: until day 15
|
NxTAG® Respiratory Pathogen Panel + SARS-CoV-2 (Luminex, Cat: X056C0470) detects and differentiates nucleic acids from SARS-CoV-2 and the following organism types and subtypes: Influenza A, Influenza A H1, Influenza A H3, Influenza B, Influenza A 2009 H1N1, Legionella pneumophila, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Bocavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.
|
until day 15
|
supplemental oxygen requirement
Time Frame: until day 15
|
until day 15
|
|
modified 10 point BORG scale
Time Frame: day 1 to day 5
|
a higher score means a worse condition
|
day 1 to day 5
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Arschang Valipour, MD, Karl Landsteiner Society; Clinic Floridsdorf
- Principal Investigator: Georg-Christian Funk, MD, Karl Landsteiner Society, Clinic Ottakring
- Principal Investigator: Wolfgang Hoeppler, MD, Gesundheitsverbund Klinik Favoriten
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVID-19/TCP_20_05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Ricardo Pereira MestreInstitute of Oncology Research (IOR); Istituto Cantonale di PatologiaCompleted
-
Livzon Pharmaceutical Group Inc.Simoon Record Pharma Information Consulting Co., Ltd.; Guangdong Center for...Completed
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Spanish Clinical Research Network - SCReNActive, not recruiting
-
Inmunova S.A.Hospital Italiano de Buenos Aires; Laboratorio Elea Phoenix S.A.; Hospital de... and other collaboratorsCompleted
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompleted
-
Rush University Medical CenterHospital Civil de GuadalajaraCompletedCovid19United States, Mexico
-
Evelyne D.TrottierCompleted
-
Sinovac Research and Development Co., Ltd.Completed
Clinical Trials on Carragelose
-
Marinomed Biotech AGRecruiting